If hot flashes are disrupting sleep or work, an antidepressant-class medicine can sound confusing.
The evidence signal is real: in MsFLASH, venlafaxine ER 75 mg/day reduced vasomotor symptoms by 47.6% over 8 weeks versus 28.6% with placebo. [3] The missing nuance is that "selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor" is a category, not a single decision.
Paroxetine 7.5 mg has the menopause-specific FDA label. Venlafaxine and escitalopram have randomized trial evidence but are typically used off-label for vasomotor symptoms. Each option brings different interaction, blood-pressure, withdrawal, sexual-side-effect, sleep, mood, and safety questions. [4] [5] [6] [7]
Bottom line
Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors are legitimate nonhormonal hot-flash treatments, especially when hormone therapy is not appropriate, not wanted, or not enough of the answer. The 2023 North American Menopause Society nonhormone statement lists selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors as Level I recommended therapies for vasomotor symptoms. [1]
The evidence is not limited in the way it is for many supplement claims, but it is still bounded: trials usually measured weeks to months, drug choice was not interchangeable, and the long-term plan depends on side effects, interactions, and whether symptoms return after tapering. [2] [3] [4] [5]
The right decision is not "try any antidepressant." It is a fit question: menopausal symptom severity, mood symptoms, sleep disruption, blood pressure, tamoxifen use, other serotonergic medicines, bleeding-risk medicines, bipolar history, sexual side effects, withdrawal sensitivity, and whether a labeled menopause option matters.
An eligibility-aware assessment is useful because the same evidence can point to different choices. A woman with bothersome hot flashes, anxiety symptoms, and normal blood pressure may rank venlafaxine or escitalopram differently from a woman taking tamoxifen, a woman with uncontrolled hypertension, or a woman whose main problem is vaginal dryness rather than hot flashes.
What current guidance says
The 2023 Menopause Society nonhormone position statement recommends selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors as Level I options for vasomotor symptoms. In that same treatment universe, cognitive-behavioral therapy, clinical hypnosis, gabapentin, and fezolinetant are also Level I options; oxybutynin is Levels I-II; and clonidine is listed among therapies not recommended. [1]
That ranking matters. Selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors are not fallback folklore. They sit among the best-supported nonhormonal medication options, but they still need individual drug selection.
| Option | Evidence posture | Label posture | Main decision issue |
|---|---|---|---|
| Paroxetine 7.5 mg | Phase 3 menopause trials support reduced hot-flash frequency. [5] | FDA-labeled for moderate to severe menopausal vasomotor symptoms. [6] | Tamoxifen/CYP2D6 warning, selective serotonin reuptake inhibitor warnings, pregnancy contraindication, and psychiatric-dose confusion. [6] |
| Venlafaxine ER | MsFLASH showed 47.6% symptom reduction over 8 weeks versus 28.6% placebo. [3] | Psychiatric label, not menopause-specific labeling. [7] | Blood-pressure monitoring, discontinuation syndrome, serotonin syndrome, and serotonin-norepinephrine reuptake inhibitor tolerability. [7] |
| Escitalopram | Randomized trial showed 4.60 fewer daily hot flashes versus 3.20 with placebo at week 8. [4] | Psychiatric label, not menopause-specific labeling. | selective serotonin reuptake inhibitor class issues, relapse after stopping in the trial, sexual side effects, and interaction review. [4] |
| Citalopram/desvenlafaxine | Included among effective agents in systematic review evidence. [2] | Usually off-label for vasomotor symptoms. | Fit depends on dose, side effects, interactions, and clinician familiarity. |
| Fluoxetine/sertraline | Review found less consistent benefit than several alternatives. [2] | Psychiatric labeling. | Often not the first hot-flash choice unless another reason favors them. [2] |
How much benefit did trials show?
The cleanest practical comparison is the MsFLASH randomized trial. It enrolled 339 peri- and postmenopausal women with at least two bothersome vasomotor symptoms per day. Baseline frequency averaged 8.1 vasomotor symptoms per day. Participants received low-dose oral estradiol, venlafaxine ER 75 mg/day, or placebo for 8 weeks. [3]
| MsFLASH arm | Participants | Week-8 frequency | Percent reduction | Difference versus placebo |
|---|---|---|---|---|
| Estradiol 0.5 mg/day | 97 | 3.9 symptoms/day | 52.9% | 2.3 fewer symptoms/day. [3] |
| Venlafaxine ER 75 mg/day | 96 | 4.4 symptoms/day | 47.6% | 1.8 fewer symptoms/day. [3] |
| Placebo | 146 | 5.5 symptoms/day | 28.6% | Reference group. [3] |
For someone starting near eight episodes a day, venlafaxine did not erase symptoms, but the average burden dropped toward four to five episodes a day. That can be clinically meaningful when the issue is sleep interruption, meetings, clothing changes, or repeated night sweating.
Escitalopram also has direct randomized evidence. In a trial of 205 women, escitalopram 10 to 20 mg/day reduced mean hot-flash frequency by 4.60 per day at week 8 versus 3.20 per day with placebo, a difference of 1.41 daily episodes. A reduction of at least 50% occurred in 55% of women on escitalopram versus 36% on placebo. [4]
The escitalopram trial also shows why follow-up matters. Three weeks after treatment stopped, women who had been on escitalopram had 1.59 more hot flashes per day than women who had been on placebo. [4] Stopping can change symptom burden, and separate selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor withdrawal issues may also matter depending on the medication.
Paroxetine 7.5 mg has the menopause-specific label and phase 3 evidence. Two randomized phase 3 trials included 591 participants assigned to paroxetine 7.5 mg and 593 assigned to placebo. The 24-week study met all primary endpoints, and the 12-week study met three of four primary endpoints; frequency was reduced at weeks 4 and 12, with benefit through week 24 in the longer trial. [5]
Paroxetine 7.5 mg: the labeled menopause option
Brisdelle is paroxetine 7.5 mg once daily at bedtime. DailyMed states it is indicated for moderate to severe vasomotor symptoms associated with menopause. The same label states that Brisdelle is not indicated for psychiatric conditions and that its dosage is lower than paroxetine doses used for psychiatric disorders. [6]
That dose distinction matters because people often hear "paroxetine" and assume it means a psychiatric-dose antidepressant plan. Brisdelle uses a low dose for a menopause indication, but it still carries selective serotonin reuptake inhibitor-class warnings and paroxetine-specific interaction concerns. [6]
| Brisdelle label issue | What to know before using it for hot flashes |
|---|---|
| Dose | 7.5 mg once daily at bedtime. [6] |
| Indication | Moderate to severe vasomotor symptoms associated with menopause. [6] |
| Not psychiatric treatment | The label says it is not indicated for psychiatric conditions. [6] |
| Contraindications | MAOI use within 14 days, thioridazine, pimozide, hypersensitivity, and pregnancy. [6] |
| Tamoxifen | Paroxetine strongly inhibits CYP2D6 and may reduce tamoxifen efficacy; the label says to consider avoiding concomitant use. [6] |
| Serotonin syndrome | Risk can occur, especially with other serotonergic drugs or MAOIs. [6] |
| Bleeding | Risk is increased with medicines that affect hemostasis, including NSAIDs, aspirin, and anticoagulants. [6] |
| Hyponatremia | SIADH and sodium below 110 mmol/L have been reported; older adults, diuretic use, and volume depletion raise concern. [6] |
| Bone fracture association | The label notes epidemiologic studies associating selective serotonin reuptake inhibitors with bone fractures. [6] |
| Mania/seizures/glaucoma | Screen for bipolar disorder, use caution with seizure history, and consider angle-closure glaucoma risk. [6] |
The tamoxifen point is the biggest paroxetine-specific fork. For a woman taking tamoxifen for breast-cancer risk reduction or treatment, the label warning should usually push the discussion toward oncology-coordinated alternatives instead of casual paroxetine use. [6]
Venlafaxine: strong trial signal, but blood pressure and stopping matter
Venlafaxine is an serotonin-norepinephrine reuptake inhibitor. In vasomotor-symptom care, it is often discussed because the MsFLASH trial used venlafaxine ER 75 mg/day and showed a symptom reduction close to low-dose estradiol in that 8-week study, though estradiol produced a slightly larger reduction. [3]
The tradeoff is that venlafaxine's current label is not a menopause hot-flash label. DailyMed labeling for venlafaxine hydrochloride extended-release capsules covers psychiatric indications and includes the usual antidepressant boxed warning for suicidal thoughts and behaviors in pediatric and young adult patients. It also lists contraindications for hypersensitivity and MAOI use within 14 days. [7]
For midlife hot-flash decisions, the practical venlafaxine label issues are blood pressure, serotonin syndrome, bleeding risk, angle-closure glaucoma, mania or hypomania activation, seizures, hyponatremia, and discontinuation syndrome. The label says blood pressure should be controlled before starting and monitored during treatment. In premarketing studies, 1.4% of venlafaxine-treated patients had a diastolic blood-pressure rise of at least 15 mm Hg to at least 105 mm Hg, compared with 0.9% on placebo; 1% had a systolic rise of at least 20 mm Hg to at least 180 mm Hg, compared with 0.3% on placebo. [7]
The discontinuation warning is also important. The label describes symptoms such as dizziness, shock-like sensations, anxiety, irritability, insomnia, nausea, sensory disturbances, and other symptoms after dose reduction or stopping, and says gradual reduction may be needed, sometimes over several months. [7]
Escitalopram: useful evidence, but not a menopause-specific label
Escitalopram is a selective serotonin reuptake inhibitor with direct hot-flash randomized controlled trial evidence. The 205-woman trial included women with frequent menopausal hot flashes and used escitalopram 10 to 20 mg/day. At week 8, daily hot-flash frequency fell 4.60 episodes with escitalopram versus 3.20 with placebo, and 55% of escitalopram users had at least a 50% reduction versus 36% on placebo. [4]
That makes escitalopram a credible nonhormonal option to discuss, especially when anxiety or depressive symptoms are also part of the clinical picture. But it should not be oversold as a labeled menopause drug. The evidence supports the hot-flash effect; the prescribing conversation still has to cover psychiatric history, other serotonergic medicines, bleeding-risk medicines, sexual side effects, sleep effects, tapering, and what to do if symptoms return after stopping. [4]
Who antidepressant-class medicines may fit
Selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors may fit when hot flashes or night sweats are moderate to severe, hormone therapy is not appropriate or not preferred, and the person wants an oral nonhormonal prescription option with randomized-trial evidence. [1] [2]
They may be especially relevant when vasomotor symptoms overlap with anxiety, depressed mood, irritability, or sleep disruption, but overlap is not the same as automatic fit. A clinician still has to decide whether the chosen medicine matches the whole medication list and medical history.
They can also be useful when estrogen is being avoided, but cancer history and tamoxifen use change the interaction review. Paroxetine's tamoxifen warning is not a minor footnote; it is a reason to slow down and coordinate the plan. [6]
Who should usually slow down or avoid shortcutting
Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors are poor shortcuts when the symptom pattern is not clearly vasomotor, when severe mood symptoms need dedicated psychiatric care, or when red flags suggest another diagnosis: chest pain, fainting, fever, unexplained weight loss, new neurologic symptoms, severe palpitations, or abnormal bleeding after menopause.
They also require stricter review when any of these are present:
- Tamoxifen use, especially with paroxetine because of CYP2D6 inhibition and the Brisdelle label warning. [6]
- MAOI use within 14 days, pimozide, thioridazine, known hypersensitivity, or pregnancy for paroxetine 7.5 mg. [6]
- Bipolar disorder, mania or hypomania history, seizure disorder, angle-closure glaucoma risk, or prior serotonin syndrome. [6] [7]
- Uncontrolled hypertension or a history of significant blood-pressure elevation, especially before venlafaxine. [7]
- Bleeding-risk medicines such as anticoagulants, antiplatelets, aspirin, frequent NSAID use, or a bleeding history. [6] [7]
- Hyponatremia risk, including older age, diuretic use, volume depletion, or prior SIADH. [6] [7]
- A history of severe discontinuation symptoms after antidepressants or difficulty tapering medicines. [7]
Decision table: paroxetine vs venlafaxine vs escitalopram
| Situation | Option that often deserves discussion | Why |
|---|---|---|
| Wants an FDA-labeled menopause option | Paroxetine 7.5 mg | Brisdelle is labeled for moderate to severe menopausal vasomotor symptoms. [6] |
| Takes tamoxifen | Avoid shortcutting to paroxetine; coordinate alternatives | The Brisdelle label warns paroxetine may reduce tamoxifen efficacy and says to consider avoiding concomitant use. [6] |
| Blood pressure is uncontrolled or labile | Be cautious with venlafaxine | The venlafaxine label says to control blood pressure before starting and monitor during treatment. [7] |
| Anxiety or depressed mood overlaps with hot flashes | Escitalopram or an serotonin-norepinephrine reuptake inhibitor may be considered, depending on history | Escitalopram and venlafaxine both have hot-flash trial evidence, but psychiatric goals need separate review. [3] [4] |
| Main issue is night sweats plus insomnia, without mood symptoms | Compare with gabapentin or hormone-therapy eligibility | selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors can help hot flashes, but night-dominant symptoms may rank other options differently. [1] |
| Wants to avoid sexual side effects or withdrawal symptoms | Slow down and compare all nonhormonal choices | selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor tolerability varies by person, and tapering can matter. [6] [7] |
| Needs fastest possible relief | Set expectations around weeks, not one dose | A review reported benefits can begin in the first week, but major trials measured 8 to 24 weeks. [2] [3] [4] [5] |
What to ask a clinician
- Are my symptoms clearly vasomotor symptoms, or do palpitations, fever, thyroid disease, medication effects, anxiety, infection, or abnormal bleeding need workup first?
- Is hormone therapy appropriate to compare, or are we choosing only among nonhormonal options?
- If choosing a selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor, why this specific one: paroxetine 7.5 mg, venlafaxine ER, escitalopram, desvenlafaxine, citalopram, or another option?
- Do I take tamoxifen, other serotonergic medicines, anticoagulants, antiplatelets, aspirin, NSAIDs, migraine medicines, stimulants, or medications that affect sodium?
- What are my baseline blood pressure, sodium risk, seizure history, bipolar history, glaucoma risk, sexual-side-effect priorities, and withdrawal history?
- How will we measure success: daily hot-flash frequency, night sweats, sleep, severity, mood, function, or a 50% reduction target?
- If the medicine helps, how long should I stay on it, and what is the taper plan if I stop?
Related reading:
- Fezolinetant vs hormone replacement therapy for hot flashes after menopause.
- Gabapentin for hot flashes after menopause.
- Oxybutynin for hot flashes after menopause.
- Clonidine for hot flashes after menopause.
- hormone replacement therapy contraindications after menopause.
References
[1] New Collective Author. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023;30(6):573-590. doi:10.1097/gme.0000000000002200 https://pubmed.ncbi.nlm.nih.gov/37252752/
[2] Handley AP, Williams M. The efficacy and tolerability of SSRI/SNRIs in the treatment of vasomotor symptoms in menopausal women: a systematic review. J Am Assoc Nurse Pract. 2015;27(1):54-61. doi:10.1002/2327-6924.12137 https://pubmed.ncbi.nlm.nih.gov/24944075/
[3] Joffe H, Guthrie KA, LaCroix AZ, et al. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. JAMA Intern Med. 2014;174(7):1058-66. doi:10.1001/jamainternmed.2014.1891 https://pubmed.ncbi.nlm.nih.gov/24861828/
[4] Freeman EW, Guthrie KA, Caan B, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA. 2011;305(3):267-74. doi:10.1001/jama.2010.2016 https://pubmed.ncbi.nlm.nih.gov/21245182/
[5] Simon JA, Portman DJ, Kaunitz AM, et al. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials. Menopause. 2013;20(10):1027-35. doi:10.1097/gme.0b013e3182a66aa7 https://pubmed.ncbi.nlm.nih.gov/24045678/
[6] DailyMed Brisdelle paroxetine capsule label. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=502311b3-b617-4cbd-a3ab-a60f2c62880a
[7] DailyMed venlafaxine hydrochloride extended-release capsule label. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f32ca617-66e0-41d8-e053-2a95a90ae40a